Skip to content
Screener

Cullinan Therapeutics, Inc. CGEM Q4 2025 Annual earnings

Reported March 10, 2026 · Before market open

EPS-$0.77Beat by $0.03
Revenue estimate$5.0M
EPS estimate-$0.80

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.0M
EPS estimate-$0.84

Financials

Q4 2025

Income statement

See full
Operating income-$55.3M-0.4%
Net income-$50.7M-6.4%

Balance sheet

See full
Cash & equivalents$88.3M+6.4%
Total debt$2.7M+24.7%
Total equity$408.7M-30.8%
Total assets$448.4M-27.9%

Cash flow

See full
Operating cash flow-$38.1M-4.0%
CapEx$11.0K—
Free cash flow-$38.1M-4.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$611.44M-13.8%
Enterprise value$525.79M-16.3%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0×0.0×
Current ratio10.2×-3.3×

FAQ

When did Cullinan Therapeutics, Inc. report Q4 2025 earnings?
Cullinan Therapeutics, Inc. (CGEM) reported Q4 2025 earnings on March 10, 2026 before market open.
What were Cullinan Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Cullinan Therapeutics, Inc. reported eps of $-0.77 for Q4 2025.
Did Cullinan Therapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.80 by $0.03.
How did Cullinan Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 5.5% from $-0.73.
Where can I find Cullinan Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-099355) and the 10-K periodic report (0001193125-26-099362) directly on SEC EDGAR. The filing index links above go to sec.gov.